LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Viatris Inc

Closed

SectorHealthcare

9.61 0.52

Overview

Share price change

24h

Current

Min

9.5

Max

9.85

Key metrics

By Trading Economics

Income

3B

-4.6M

Sales

328M

3.6B

Dividend yield

4.82

Profit margin

-0.128

Employees

32,000

EBITDA

2.9B

578M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+7.22% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.82%

3.07%

Next Earnings

6 lis 2025

Next Dividend date

12 gru 2025

Next Ex Dividend date

21 lis 2025

Market Stats

By TradingEconomics

Market Cap

1.1B

12B

Previous open

9.09

Previous close

9.61

News Sentiment

By Acuity

50%

50%

167 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Viatris Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 wrz 2025, 23:01 UTC

Acquisitions, Mergers, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 wrz 2025, 22:48 UTC

Acquisitions, Mergers, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 wrz 2025, 21:59 UTC

Earnings

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 wrz 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17 wrz 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 wrz 2025, 22:20 UTC

Acquisitions, Mergers, Takeovers

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 wrz 2025, 22:20 UTC

Acquisitions, Mergers, Takeovers

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 wrz 2025, 22:20 UTC

Acquisitions, Mergers, Takeovers

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 wrz 2025, 22:19 UTC

Acquisitions, Mergers, Takeovers

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 wrz 2025, 22:18 UTC

Acquisitions, Mergers, Takeovers

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 wrz 2025, 21:00 UTC

Earnings

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 wrz 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17 wrz 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 wrz 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 wrz 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 wrz 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 wrz 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 wrz 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 wrz 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 wrz 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 wrz 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 wrz 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 wrz 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 wrz 2025, 17:15 UTC

Acquisitions, Mergers, Takeovers

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 wrz 2025, 17:06 UTC

Acquisitions, Mergers, Takeovers

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 wrz 2025, 16:51 UTC

Earnings

Correct: Exor 1H Net Loss -EUR624M

17 wrz 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 wrz 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 wrz 2025, 16:25 UTC

Earnings

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 wrz 2025, 16:23 UTC

Earnings

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Peer Comparison

Price change

Viatris Inc Forecast

Price Target

By TipRanks

7.22% upside

12 Months Forecast

Average 10.25 USD  7.22%

High 14 USD

Low 8 USD

Based on 4 Wall Street analysts offering 12 month price targets forViatris Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

0

Buy

3

Hold

1

Sell

Technical Score

By Trading Central

8.48 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

167 / 371 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
help-icon Live chat